Governmental Non-Pharmaceutical Interventions during the COVID-19 Pandemic and the COPD Exacerbation and Respiratory Infection Rate in Patients with Alpha-1 Antitrypsin Deficiency

References

• Tan JY, Conceicao EP, Wee LE, et al. COVID-19 public health measures: a reduction in hospital admissions for COPD exacerbations. Thorax. 2021;76(5):512–513. doi: 10.1136/thoraxjnl-2020-216083.
   PubMed Web of Science ®Google Scholar
• So JY, O’Hara NN, Kenaa B, et al. Population decline in COPD admissions During the COVID-19 pandemic associated with lower burden of community respiratory viral infections. Am J Med. 2021;134(10):1252–1259.e3. doi: 10.1016/j.amjmed.2021.05.008.
   PubMed Web of Science ®Google Scholar
• Alqahtani JS, Oyelade T, Aldhahir AM, et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(8):e0255659. doi: 10.1371/journal.pone.0255659.
   PubMed Web of Science ®Google Scholar
• McAuley H, Hadley K, Elneima O, et al. COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD. ERJ Open Research. 2021;7(1). doi: 10.1183/23120541.00718-2020.
   PubMedGoogle Scholar
• Waeijen-Smit K, Houben-Wilke S, Posthuma R, et al. Impact of coronavirus disease 2019 related infection prevention and control measures on the occurrence of COPD exacerbations during inpatien pulmonary rehabilitation. Chronic Obstr Pulm Dis. 2023;10(2):127–138. doi: 10.15326/jcopdf.2022.0345.
   PubMed Web of Science ®Google Scholar
• Cheng DO, Hurst JR. COVID-19 and ‘basal’ exacerbation frequency in COPD. Thorax. 2021;76(5):432–433. doi: 10.1136/thoraxjnl-2020-216637.
   PubMed Web of Science ®Google Scholar
• Trujillo C, Garnet B, Zadeh AV, et al. Decrease in exacerbations during the coronavirus disease 2019 pandemic in a cohort of veterans with COPD. Chronic Obstr Pulm Dis. 2021;8(4):572–579. doi: 10.15326/jcopdf.2021.0234.
   PubMed Web of Science ®Google Scholar
• Alsallakh MA, Sivakumaran S, Kennedy S, et al. Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales. BMC Med. 2021;19(1):124. doi: 10.1186/s12916-021-02000-w.
   PubMed Web of Science ®Google Scholar
• Sarc I, Lotric Dolinar A, Morgan T, et al. Mortality, seasonal variation, and susceptibility to acute exacerbation of COPD in the pandemic year: a nationwide population study. Ther Adv Respir Dis. 2022;16:17534666221081047. doi: 10.1177/17534666221081047.
   Web of Science ®Google Scholar
• Strnad P, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382(15):1443–1455. doi: 10.1056/NEJMra1910234.
   PubMed Web of Science ®Google Scholar
• Hale T, Angrist N, Goldszmidt R, et al. A global panel database of pandemic policies (Oxford COVID-19 government response tracker). Nat Hum Behav. 2021;5(4):529–538. doi: 10.1038/s41562-021-01079-8.
   PubMed Web of Science ®Google Scholar
• al. EMe. Coronavirus Pandemic (COVID-19); 2020. [cited 2023 January 15]. Available at https://ourworldindata.org/coronavirus.
   Google Scholar
• Seixas S, Marques PI. Known mutations at the cause of alpha-1 antitrypsin deficiency an updated overview of SERPINA1 variation spectrum. Appl Clin Genet. 2021;14:173–194. doi: 10.2147/TACG.S257511.
   PubMed Web of Science ®Google Scholar
• Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of respiratory viral infections. Annu Rev Virol. 2020;7(1):83–101. doi: 10.1146/annurev-virology-012420-022445.
   PubMed Web of Science ®Google Scholar
• Hicks A, Healy E, Sandeman N, et al. A time for everything and everything in its time - exploring the mechanisms underlying seasonality of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2018;13:2739–2749. doi: 10.2147/COPD.S146015.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Cumella A, Niklewicz CN, et al. Acceptability of hygiene, face covering and social distancing interventions to prevent exacerbations in people living with airways diseases. Thorax. 2022;77(5):505–507. doi: 10.1136/thoraxjnl-2021-217981.
   PubMed Web of Science ®Google Scholar
• Lawless M, Burgess M, Bourke S. Impact of COVID-19 on hospital admissions for COPD exacerbation: lessons for future care. Medicina. 2022;58(1):66. doi: 10.3390/medicina58010066.
   PubMedGoogle Scholar
• Barrecheguren M, Miravitlles M. Treatment with inhaled α1-antitrypsin: a square peg in a round hole? Eur Respir J. 2019;54(5). doi: 10.1183/13993003.01894-2019.
   PubMed Web of Science ®Google Scholar
• Stolk J, Tov N, Chapman KR, et al. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;54(5). doi: 10.1183/13993003.00673-2019.
   PubMed Web of Science ®Google Scholar
• Ashenhurst JR, Nhan H, Shelton JF, et al. Prevalence of alpha-1 antitrypsin deficiency, self-reported behavior change, and health care engagement among direct-to-consumer recipients of a personalized genetic risk report. Chest. 2022;161(2):373–381. doi: 10.1016/j.chest.2021.09.041.
   PubMed Web of Science ®Google Scholar